More Avecho Biotechnology Limited news
Avecho Biotechnology LimitedASX: AVE

Appendix 4E and Annual Report 31 December 2023

Feb 29, 2024 at 6:54 AM EST · Issued by Avecho Biotechnology Limited

Filed with ASX · Feb 29, 2024 at 6:54 AM EST

On 6ix: 6ix.com/news/appendix-4e-and-annual-report-31-december-2023

Avecho Biotechnology Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Avecho Biotechnology Limited on 6ix

Story so far

  • Appendix 4E and Annual Report 31 December 2021Feb 28, 2022

Earlier from Avecho Biotechnology

  • December 2023 Quarterly Activities Report & Appendix 4CJan 30, 2024
  • September 2023 Quarterly Activities Report & Appendix 4COct 30, 2023
  • Reinstatement to Official QuotationAug 28, 2023
  • Avecho raises further $6M for Phase III trialAug 28, 2023
  • Voluntary SuspensionAug 24, 2023

Later from Avecho Biotechnology

  • AVE receives final ethics approval for Phase III CBD trialMar 6, 2024
  • Avecho meets TGA ahead of Phase III Clinical TrialMar 13, 2024
  • Avecho commences Phase III insomnia trialMar 25, 2024
  • March 2024 Quarterly Activities Report & Appendix 4CApr 30, 2024
  • First Patient dosed in Phase III insomnia trialMay 15, 2024
All Avecho Biotechnology news releases↗

Follow Avecho Biotechnology into a list and get an email when it puts out news.

Follow Avecho Biotechnology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer